China Sky One Medical, Inc. to Present at Rodman & Renshaw Annual Global Investment Conference and Conduct Non-Deal Roadshow in the U.S.

HARBIN, China, Sept. 1 /PRNewswire-Asia-FirstCall/ — China Sky One
Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People’s Republic of China (“PRC”), today announced the Company
will present at the upcoming Rodman & Renshaw Annual Global Investment
Conference to be held on September 9-11 at the New York Palace Hotel in New
York City. The Company will also conduct a non-deal roadshow in the U.S.
during the week of September 14.

The Rodman & Renshaw Annual Global Investment Conference is a three-day
event which features tracks devoted to Healthcare, Metals & Mining, Energy,
Clean-tech, Asia, Community & Regional Banks, Growth, & Maritime. So far, more
than 500 companies have registered to attend the conference. Schedule of China
Sky One Medical’s presentation is as follows:

    Date:     Thursday, September 10th, 2009
    Time:     10:25 a.m. Eastern Time
    Venue:    Louis Salon (4th Floor)
              New York Palace Hotel
              455 Madison Avenue, NY 10022

During the conference, the Company will be available for one-on-one
meetings. For more information about the conference, please visit
http://www.rodm.com/conferences .

To complement its participation at the conference, China Sky One Medical
is also scheduled to launch a non-deal roadshow in the U.S. from September
14-18. Mr. Yan-qing Liu, Chairman and CEO of the Company, and Mr. Stanley Hao,
the CFO of China Sky One Medical, will meet with securities analysts and
investors in Boston, Chicago, Denver, San Francisco and Los Angeles.

“We are excited to participate in the upcoming conference and conduct a
non-deal roadshow in the U.S.,” commented Mr. Yan-qing Liu, Chairman and CEO
of China Sky One Medical. “This is a unique opportunity for us to present
China Sky One Medical’s story to meet the investment community and provide an
update on our business plan and growth strategy. We value effective and
direct communication with our shareholders and potential investors.”

The non-deal roadshow is being hosted by CCG Investor Relations. A copy of
the presentation to be used for the conference and the roadshow will be posted
on the Company’s website at http://www.cski.com.cn on or before September 10,
2009.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
(“TDR”), Harbin First Bio- Engineering Company Limited (“First”), Heilongjiang
Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang
Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue
source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the use
of forward- looking terminology such as “believe,” “expect,” “may,” “will,”
“should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative
thereof or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
the attendance of investment conferences and non-deal road show meetings.
Actual results could differ materially from the expectations reflected in such
forward-looking statements as a result of a variety of factors, including the
risks associated with the effect of changing economic conditions in The
People’s Republic of China, variations in cash flow, reliance on collaborative
retail partners and on new product development, variations in new product
development, risks associated with rapid technological change, and the
potential of introduced or undetected flaws and defects in products, and other
risk factors detailed in reports filed with the Securities and Exchange
Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-5399-4069
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.